Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma Patients

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic <i>BRAF</i> or <i>NRAS</i>-Mutated Melanoma Patients

Circulating tumour DNA (ctDNA) can be used to identify gene alterations. The purpose of this study was to determine whether the detection of ctDNA, based on the identification of <i>BRAF</i> and <i>NRAS</i> mutations before systemic treatment initiation, was associated with t...

Full description

Bibliographic Details
Main Authors: Guillaume Herbreteau, Audrey Vallée, Anne-Chantal Knol, Sandrine Théoleyre, Gaelle Quéreux, Cécile Frénard, Emilie Varey, Paul Hofman, Amir Khammari, Brigitte Dréno, Marc G. Denis
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
melanoma
circulating tumour DNA
BRAF
NRAS
mutation
prognosis
Online Access:https://www.mdpi.com/2072-6694/12/7/1871

Internet

https://www.mdpi.com/2072-6694/12/7/1871

Similar Items